A preclinical study has reported successful outcomes with antibody therapy targeting galectin-3 in pancreatic cancers via EGFR, indicating that galectin-3 blockade reduced tumor cell migration, adhesion, and invasion [43]. Here, LGALS3 is linked to neoplasm.